Literature DB >> 17707266

Clinically significant prostate cancer local recurrence after radiation therapy occurs at the site of primary tumor: magnetic resonance imaging and step-section pathology evidence.

Darko Pucar1, Hedvig Hricak, Amita Shukla-Dave, Kentaro Kuroiwa, Marija Drobnjak, James Eastham, Peter T Scardino, Michael J Zelefsky.   

Abstract

PURPOSE: To determine whether prostate cancer local recurrence after radiation therapy (RT) occurs at the site of primary tumor by retrospectively comparing the tumor location on pre-RT and post-RT magnetic resonance imaging (MRI) and using step-section pathology after salvage radical prostatectomy (SRP) as the reference standard. METHODS AND MATERIALS: Nine patients with localized prostate cancer were treated with intensity modulated RT (69-86.4 Gy), and had pre-RT and post-RT prostate MRI, biopsy-proven local recurrence, and SRP. The location and volume of lesions on pre-RT and post-RT MRI were correlated with step-section pathology findings. Tumor foci >0.2 cm(3) and/or resulting in extraprostatic disease on pathology were considered clinically significant.
RESULTS: All nine significant tumor foci (one in each patient; volume range, 0.22-8.63 cm(3)) were detected both on pre-RT and post-RT MRI and displayed strikingly similar appearances on pre-RT and post-RT MRI and step-section pathology. Two clinically insignificant tumor foci (</=0.06 cm(3)) were not detected on imaging. The ratios between tumor volumes on pathology and on post-RT MRI ranged from 0.52 to 2.80.
CONCLUSIONS: Our study provides a direct visual confirmation that clinically significant post-RT local recurrence occurs at the site of primary tumor. Our results are in agreement with reported clinical and pathologic results and support the current practice of boosting the radiation dose within the primary tumor using imaging guidance. They also suggest that monitoring of primary tumor with pre-RT and post-RT MRI could lead to early detection of local recurrence amenable to salvage treatment.

Entities:  

Mesh:

Year:  2007        PMID: 17707266     DOI: 10.1016/j.ijrobp.2007.03.065

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  77 in total

Review 1.  Functional MRI for radiotherapy dose painting.

Authors:  Uulke A van der Heide; Antonetta C Houweling; Greetje Groenendaal; Regina G H Beets-Tan; Philippe Lambin
Journal:  Magn Reson Imaging       Date:  2012-07-06       Impact factor: 2.546

Review 2.  Tracer kinetic modelling of tumour angiogenesis based on dynamic contrast-enhanced CT and MRI measurements.

Authors:  Gunnar Brix; Jürgen Griebel; Fabian Kiessling; Frederik Wenz
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-08       Impact factor: 9.236

3.  Spatiotemporal stability of Cu-ATSM and FLT positron emission tomography distributions during radiation therapy.

Authors:  Tyler J Bradshaw; Stephen Yip; Ngoneh Jallow; Lisa J Forrest; Robert Jeraj
Journal:  Int J Radiat Oncol Biol Phys       Date:  2014-03-28       Impact factor: 7.038

4.  Volumetric modulated arc therapy planning for primary prostate cancer with selective intraprostatic boost determined by 18F-choline PET/CT.

Authors:  Yu Kuang; Lili Wu; Emily Hirata; Kyle Miyazaki; Miles Sato; Sandi A Kwee
Journal:  Int J Radiat Oncol Biol Phys       Date:  2015-04-01       Impact factor: 7.038

Review 5.  Overview of dynamic contrast-enhanced MRI in prostate cancer diagnosis and management.

Authors:  Sadhna Verma; Baris Turkbey; Naira Muradyan; Arumugam Rajesh; Francois Cornud; Masoom A Haider; Peter L Choyke; Mukesh Harisinghani
Journal:  AJR Am J Roentgenol       Date:  2012-06       Impact factor: 3.959

Review 6.  Advances in Prostate Cancer Magnetic Resonance Imaging and Positron Emission Tomography-Computed Tomography for Staging and Radiotherapy Treatment Planning.

Authors:  Drew Moghanaki; Baris Turkbey; Neha Vapiwala; Behfar Ehdaie; Steven J Frank; Patrick W McLaughlin; Mukesh Harisinghani
Journal:  Semin Radiat Oncol       Date:  2016-08-31       Impact factor: 5.934

7.  Dosimetric benefit of DMLC tracking for conventional and sub-volume boosted prostate intensity-modulated arc radiotherapy.

Authors:  Tobias Pommer; Marianne Falk; Per R Poulsen; Paul J Keall; Ricky T O'Brien; Peter Meidahl Petersen; Per Munck af Rosenschöld
Journal:  Phys Med Biol       Date:  2013-03-14       Impact factor: 3.609

Review 8.  Patterns of outcome and toxicity after salvage prostatectomy, salvage cryosurgery and salvage brachytherapy for prostate cancer recurrences after radiation therapy: a multi-center experience and literature review.

Authors:  Max Peters; Maaike R Moman; Henk G van der Poel; Henk Vergunst; Igle Jan de Jong; Peter L M Vijverberg; Jan J Battermann; Simon Horenblas; Marco van Vulpen
Journal:  World J Urol       Date:  2012-08-18       Impact factor: 4.226

9.  [Prostate cancer].

Authors:  T Franiel; N Eckardt; M Waginger; M Horstmann
Journal:  Radiologe       Date:  2014-05       Impact factor: 0.635

10.  Cold spot mapping inferred from MRI at time of failure predicts biopsy-proven local failure after permanent seed brachytherapy in prostate cancer patients: implications for focal salvage brachytherapy.

Authors:  Gilles Crehange; Devan Krishnamurthy; J Adam Cunha; Barby Pickett; John Kurhanewicz; I-Chow Hsu; Alexander R Gottschalk; Katsuto Shinohara; Mack Roach; Jean Pouliot
Journal:  Radiother Oncol       Date:  2013-11-11       Impact factor: 6.280

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.